Recently it attracted attention of global scientific community as it increased the lifespan of mice in animal experiments.
In cells, Sirolimus binds to the immunophilin, FK Binding Protein-12 (FKBP-12), to generate an immunosuppressive complex. This complex binds to and inhibits the activation of the mammalian Target Of Rapamycin (mTOR), a key regulatory kinase. This inhibition suppresses cytokine-driven T-cell proliferation, inhibiting the progression from the G1 to the S phase of the cell cycle.
Inhibition of T-Cells proliferation leads to no antibodies production and eventually no rejection of transplanted organs / no other immunological reactions.
- Cardiac transplant rejection
- Kidney transplant rejection
- Liver transplant rejection
- Small Bowel transplant rejection
- Pancreas transplant rejection
- Lung transplant rejection
- Trachea transplant rejection
- Skin transplant rejection
- Bone marrow transplant rejection
- Cornea transplant rejection
- Limb transplant rejection
- Dermal Kaposi's sarcoma cancer
- Mantle cell lymphoma cancer
- Glioblastoma multiforme cancer
- AKT-positive lymphoma cancer
Of several minor side effects, the important side effect is Diabetes Mellitus.
Another considerable effect - increase in the severity of existing Viral, fungal and bacterial infections and increased vulnerability to opportunistic fungal and viral infections.
i-SILIMUS Tablets are available in 1.0 mg strength.
Box containing 5 Strips of 10 tablets each